Immunological evaluation of rheumatoid arthritis patients treated with itolizumab

References

• van de Sande MG, de Hair MJ, van der Leij C, Klarenbeek PL, Bos WH, Smith MD, Maas M, de Vries N, van Schaardenburg D, Dijkmans BA, et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis 2011; 70:772-7; PMID:21177292; http://dx.doi.org/10.1136/ard.2010.139527
   PubMed Web of Science ®Google Scholar
• Sangha O. Epidemiology of rheumatic diseases. Rheumatology (Oxford) 2000; 39 Suppl 2:3-12; PMID:11276800; http://dx.doi.org/10.1093/rheumatology/39.suppl_2.3
   PubMed Web of Science ®Google Scholar
• Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358:903-11; PMID:11567728; http://dx.doi.org/10.1016/S0140-6736(01)06075-5
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964-75; PMID:20444750; http://dx.doi.org/10.1136/ard.2009.126532
   PubMed Web of Science ®Google Scholar
• Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762-84; PMID:18512708; http://dx.doi.org/10.1002/art.23721
   PubMed Web of Science ®Google Scholar
• Keystone E, Heijde D, Mason D, Jr., Landewe R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008; 58:3319-29; PMID:18975346; http://dx.doi.org/10.1002/art.23964
   PubMed Web of Science ®Google Scholar
• Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009; 68:789-96; PMID:19066176; http://dx.doi.org/10.1136/ard.2008.099010
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, Zickert A, Theander J, Thorner A, Hellstrom H, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009; 374:459-66; PMID:19665644; http://dx.doi.org/10.1016/S0140-6736(09)60944-2
   PubMed Web of Science ®Google Scholar
• Carter PH, Zhao Q. Clinically validated approaches to the treatment of autoimmune diseases. Expert Opin Investig Drugs 2010; 19:195-213; PMID:20050823; http://dx.doi.org/10.1517/13543780903418452
   PubMed Web of Science ®Google Scholar
• Panayi GS, Corrigall VM, Pitzalis C. Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum Dis Clin North Am 2001; 27:317-34; PMID:11396095; http://dx.doi.org/10.1016/S0889-857X(05)70204-0
   PubMed Web of Science ®Google Scholar
• Guzmán-Moreno R. Artritis Reumatoide. Bases inmunológicas para la terapia biológica. Rev Colom Reumatol 2003; 10:119-34; PMID:Can't
   PubMedGoogle Scholar
• Goronzy JJ, Weyand CM. T-cell regulation in rheumatoid arthritis. Curr Opin Rheumatol 2004; 16:212-7; PMID:15103247; http://dx.doi.org/10.1097/00002281-200405000-00008
   PubMed Web of Science ®Google Scholar
• Snir O, Backlund J, Bostrom J, Andersson I, Kihlberg J, Buckner JH, Klareskog L, Holmdahl R, Malmstrom V. Multifunctional T cell reactivity with native and glycosylated type II collagen in rheumatoid arthritis. Arthritis Rheum 2012; 64:2482-8; PMID:22392632; http://dx.doi.org/10.1002/art.34459
   PubMed Web of Science ®Google Scholar
• Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344:907-16; PMID:11259725; http://dx.doi.org/10.1056/NEJM200103223441207
   PubMed Web of Science ®Google Scholar
• McInnes IB. Leukotrienes, mast cells, and T cells. Arthritis Res Ther 2003; 5:288-9; PMID:14680504; http://dx.doi.org/10.1186/ar1017
   PubMed Web of Science ®Google Scholar
• Constantin A, Loubet-Lescoulie P, Lambert N, Yassine-Diab B, Abbal M, Mazieres B, de Preval C, Cantagrel A. Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum 1998; 41:48-57; PMID:9433869; http://dx.doi.org/10.1002/1529-0131(199801)41:1%3c48::AID-ART7%3e3.0.CO;2-K
   PubMed Web of Science ®Google Scholar
• Bodian DL, Skonier JE, Bowen MA, Neubauer M, Siadak AW, Aruffo A, Bajorath J. Identification of residues in CD6 which are critical for ligand binding. Biochemistry 1997; 36:2637-41; PMID:9054570; http://dx.doi.org/10.1021/bi962560+
   PubMed Web of Science ®Google Scholar
• Whitney GS, Starling GC, Bowen MA, Modrell B, Siadak AW, Aruffo A. The membrane-proximal scavenger receptor cysteine-rich domain of CD6 contains the activated leukocyte cell adhesion molecule binding site. J Biol Chem 1995; 270:18187-90; PMID:7543097; http://dx.doi.org/10.1074/jbc.270.31.18187
   PubMed Web of Science ®Google Scholar
• Zimmerman AW, Joosten B, Torensma R, Parnes JR, van Leeuwen FN, Figdor CG. Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. Blood 2006; 107:3212-20; PMID:16352806; http://dx.doi.org/10.1182/blood-2005-09-3881
   PubMed Web of Science ®Google Scholar
• Ibanez A, Sarrias MR, Farnos M, Gimferrer I, Serra-Pages C, Vives J, Lozano F. Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor. J Immunol 2006; 177:1152-9; PMID:16818773; http://dx.doi.org/10.4049/jimmunol.177.2.1152
   PubMed Web of Science ®Google Scholar
• Singer NG, Fox DA, Haqqi TM, Beretta L, Endres JS, Prohaska S, Parnes JR, Bromberg J, Sramkoski RM. CD6: expression during development, apoptosis and selection of human and mouse thymocytes. Int Immunol 2002; 14:585-97; PMID:12039910; http://dx.doi.org/10.1093/intimm/dxf025
   PubMed Web of Science ®Google Scholar
• Le Dantec C, Alonso R, Fali T, Montero E, Devauchelle V, Saraux A, Pers JO, Renaudineau Y. Rationale for treating primary Sjogren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab). Immunol Res 2013; 56:341-7; PMID:23576060; http://dx.doi.org/10.1007/s12026-013-8423-x
   PubMed Web of Science ®Google Scholar
• Alonso-Ramirez R, Loisel S, Buors C, Pers JO, Montero E, Youinou P, Renaudineau Y. Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases. Arthritis 2010; 2010:130646; PMID:22076177; http://dx.doi.org/10.1155/2010/130646
   PubMedGoogle Scholar
• Gimferrer I, Calvo M, Mittelbrunn M, Farnos M, Sarrias MR, Enrich C, Vives J, Sanchez-Madrid F, Lozano F. Relevance of CD6-mediated interactions in T cell activation and proliferation. J Immunol 2004; 173:2262-70; PMID:15294938; http://dx.doi.org/10.4049/jimmunol.173.4.2262
   PubMed Web of Science ®Google Scholar
• Hassan NJ, Barclay AN, Brown MH. Frontline: Optimal T cell activation requires the engagement of CD6 and CD166. Eur J Immunol 2004; 34:930-40; PMID:15048703; http://dx.doi.org/10.1002/eji.200424856
   PubMed Web of Science ®Google Scholar
• Kirkman RL, Araujo JL, Busch GJ, Carpenter CB, Milford EL, Reinherz EL, Schlossman SF, Strom TB, Tilney NL. Treatment of acute renal allograft rejection with monoclonal anti-T12 antibody. Transplantation 1983; 36:620-6; PMID:6197792; http://dx.doi.org/10.1097/00007890-198336060-00005
   PubMed Web of Science ®Google Scholar
• Reinherz EL, Geha R, Rappeport JM, Wilson M, Penta AC, Hussey RE, Fitzgerald KA, Daley JF, Levine H, Rosen FS, et al. Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone marrow for severe combined immunodeficiency. Proc Natl Acad Sci U S A 1982; 79:6047-51; PMID:6764536; http://dx.doi.org/10.1073/pnas.79.19.6047
   PubMed Web of Science ®Google Scholar
• Hafler DA, Fallis RJ, Dawson DM, Schlossman SF, Reinherz EL, Weiner HL. Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12. Neurology 1986; 36:777-84; PMID:3486383; http://dx.doi.org/10.1212/WNL.36.6.777
   PubMed Web of Science ®Google Scholar
• Swaminathan B, Matesanz F, Cavanillas ML, Alloza I, Otaegui D, Olascoaga J, Cenit MC, de las Heras V, Barcina MG, Arroyo R, et al. Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain. J Neuroimmunol 2010; 223:100-3; PMID:20430450; http://dx.doi.org/10.1016/j.jneuroim.2010.03.020
   PubMed Web of Science ®Google Scholar
• Johnson BA, Wang J, Taylor EM, Caillier SJ, Herbert J, Khan OA, Cross AH, De Jager PL, Gourraud PA, Cree BC, et al. Multiple sclerosis susceptibility alleles in African Americans. Genes Immun 2010; 11:343-50; PMID:19865102; http://dx.doi.org/10.1038/gene.2009.81
   PubMed Web of Science ®Google Scholar
• Alonso R, Buors C, Le Dantec C, Hillion S, Pers JO, Saraux A, Montero E, Marianowski R, Loisel S, Devauchelle V, et al. Aberrant expression of CD6 on B-cell subsets from patients with Sjogren's syndrome. J Autoimmun 2010; 35:336-41; PMID:20810246; http://dx.doi.org/10.1016/j.jaut.2010.07.005
   PubMed Web of Science ®Google Scholar
• Alonso R, Huerta V, de Leon J, Piedra P, Puchades Y, Guirola O, Chinea G, Montero E. Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody. Hybridoma (Larchmt) 2008; 27:291-301; PMID:18707547; http://dx.doi.org/10.1089/hyb.2008.0007
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Torres-Moya R, Reyes G, Molinero C, Prada D, Lopez AM, Hernandez IM, Hernandez MV, Martinez JP, Hernandez X, et al. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis. Results Immunol 2012; 2:204-11; PMID:24371585; http://dx.doi.org/10.1016/j.rinim.2012.11.001
   PubMedGoogle Scholar
• Nair P, Melarkode R, Rajkumar D, Montero E. CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction. Clin Exp Immunol 2010; 162:116-30; PMID:20726988; http://dx.doi.org/10.1111/j.1365-2249.2010.04235.x
   PubMed Web of Science ®Google Scholar
• Aira LE, Lopez-Requena A, Fuentes D, Sanchez L, Perez T, Urquiza A, Bautista H, Falcon L, Hernandez P, Mazorra Z. Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab. MAbs 2014; 6:783-93; PMID:24594862; http://dx.doi.org/10.4161/mabs.28376
   PubMed Web of Science ®Google Scholar
• Gabay C, Hasler P, Kyburz D, So A, Villiger P, von Kempis J, Walker U. Biological agents in monotherapy for the treatment of rheumatoid arthritis. Swiss Med Wkly 2014; 144:w13950; PMID:24723273
   PubMedGoogle Scholar
• Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009; 68:1870-7; PMID:19124524; http://dx.doi.org/10.1136/ard.2008.101121
   PubMed Web of Science ®Google Scholar
• Gangemi RM, Swack JA, Gaviria DM, Romain PL. Anti-T12, an anti-CD6 monoclonal antibody, can activate human T lymphocytes. J Immunol 1989; 143:2439-47; PMID:2794503
   PubMed Web of Science ®Google Scholar
• Osorio LM, Garcia CA, Jondal M, Chow SC. The anti-CD6 mAb, IOR-T1, defined a new epitope on the human CD6 molecule that induces greater responsiveness in T cell receptor/CD3-mediated T cell proliferation. Cell Immunol 1994; 154:123-33; PMID:7509726; http://dx.doi.org/10.1006/cimm.1994.1062
   PubMed Web of Science ®Google Scholar
• Krupashankar DS, Dogra S, Kura M, Saraswat A, Budamakuntla L, Sumathy TK, Shah R, Gopal MG, Narayana Rao T, Srinivas CR, et al. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol 2014; 71:484-92; PMID:24703722; http://dx.doi.org/10.1016/j.jaad.2014.01.897
   PubMed Web of Science ®Google Scholar
• Herman S, Zurgil N, Langevitz P, Ehrenfeld M, Deutsch M. The immunosuppressive effect of methotrexate in active rheumatoid arthritis patients vs. its stimulatory effect in nonactive patients, as indicated by cytometric measurements of CD4+ T cell subpopulations. Immunol Invest 2004; 33:351-62; PMID:15495793; http://dx.doi.org/10.1081/IMM-120039865
   PubMed Web of Science ®Google Scholar
• Yue C, You X, Zhao L, Wang H, Tang F, Zhang F, Zhang X, He W. The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 2010; 30:1553-7; PMID:19847432; http://dx.doi.org/10.1007/s00296-009-1179-x
   PubMed Web of Science ®Google Scholar
• Lina C, Conghua W, Nan L, Ping Z. Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis. J Clin Immunol 2011; 31:596-605; PMID:21562776; http://dx.doi.org/10.1007/s10875-011-9542-6
   PubMed Web of Science ®Google Scholar
• Marotte H, Cimaz R. Etanercept - TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers? Expert Opin Biol Ther 2014; 14:569-72; PMID:24611432; http://dx.doi.org/10.1517/14712598.2014.896334
   PubMed Web of Science ®Google Scholar
• Scarsi M, Zanotti C, Chiarini M, Imberti L, Piantoni S, Frassi M, Tincani A, Airo P. Reduction of peripheral blood T cells producing IFN-gamma and IL-17 after therapy with abatacept for rheumatoid arthritis. Clin Exp Rheumatol 2014; 32:204-10; PMID:24428959
   PubMed Web of Science ®Google Scholar
• Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103:1243-52; PMID:10225967; http://dx.doi.org/10.1172/JCI5857
   PubMed Web of Science ®Google Scholar
• Panayi GS. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? Rheumatology (Oxford) 2005; 44 Suppl 2:ii3-ii7; PMID:15851524
   PubMed Web of Science ®Google Scholar
• Lopez-Olivo MA, Amezaga Urruela M, McGahan L, Pollono EN, Suarez-Almazor ME. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev 2015; 1:CD007356; PMID:25603545
   PubMedGoogle Scholar
• Coffey G, Betz A, Graf J, Stephens G, Hua Lin P, Imboden J, Sinha U. Methotrexate and a spleen tyrosine kinase inhibitor cooperate to inhibit responses to peripheral blood B cells in rheumatoid arthritis. Pharmacol Res Perspect 2013; 1:e00016; PMID:25505569; http://dx.doi.org/10.1002/prp2.16
   PubMedGoogle Scholar
• Glaesener S, Quach TD, Onken N, Weller-Heinemann F, Dressler F, Huppertz HI, Thon A, Meyer-Bahlburg A. Distinct effects of methotrexate and etanercept on the B cell compartment in patients with juvenile idiopathic arthritis. Arthritis Rheumatol 2014; 66:2590-2600; PMID:24909567; http://dx.doi.org/10.1002/art.38736
   PubMed Web of Science ®Google Scholar
• Burska A, Boissinot M, Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm 2014; 2014:545493; PMID:24733962
   PubMed Web of Science ®Google Scholar
• Dimitroulas T, Nikas SN, Trontzas P, Kitas GD. Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun Rev 2013; 12:958-66; PMID:23542506; http://dx.doi.org/10.1016/j.autrev.2013.03.015
   PubMed Web of Science ®Google Scholar
• Olsen NJ, Spurlock CF, 3rd, Aune TM. Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res Ther 2014; 16:R17; PMID:24444433; http://dx.doi.org/10.1186/ar4444
   PubMedGoogle Scholar
• Crilly A, McInness IB, McDonald AG, Watson J, Capell HA, Madhok R. Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate. J Rheumatol 1995; 22:224-226; PMID:7738942
   PubMed Web of Science ®Google Scholar
• Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39:1951-60; PMID:8961899; http://dx.doi.org/10.1002/art.1780391203
   PubMed Web of Science ®Google Scholar
• Weisman MH, Durez P, Hallegua D, Aranda R, Becker JC, Nuamah I, Vratsanos G, Zhou Y, Moreland LW. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol 2006; 33:2162-6; PMID:17014006
   PubMed Web of Science ®Google Scholar
• Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, Radjenovic A, English A, Tang H, Vratsanos G, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009; 68:1220-7; PMID:18772191; http://dx.doi.org/10.1136/ard.2008.091876
   PubMed Web of Science ®Google Scholar
• Sarkar S, Cooney LA, White P, Dunlop DB, Endres J, Jorns JM, Wasco MJ, Fox DA. Regulation of pathogenic IL-17 responses in collagen-induced arthritis: roles of endogenous interferon-gamma and IL-4. Arthritis Res Ther 2009; 11:R158; PMID:19852819; http://dx.doi.org/10.1186/ar2838
   PubMedGoogle Scholar
• Kawakami A, Eguchi K, Matsuoka N, Tsuboi M, Urayama S, Kawabe Y, Aoyagi T, Maeda K, Nagataki S. Inhibitory effects of interleukin-10 on synovial cells of rheumatoid arthritis. Immunology 1997; 91:252-9; PMID:9227325; http://dx.doi.org/10.1046/j.1365-2567.1997.00244.x
   PubMed Web of Science ®Google Scholar
• Jullien D. ; Anti-drug antibodies, auto-antibodies and biotherapy in psoriasis. Ann Dermatol Venereol 2012; 139 Suppl 2:S58-67; PMID:22541730; http://dx.doi.org/10.1016/S0151-9638(12)70112-6
   PubMedGoogle Scholar
• Matsumoto Y, Maeda T, Tsuboi R, Okubo Y. Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases. J Dermatol 2013; 40:389-92; PMID:23414225; http://dx.doi.org/10.1111/1346-8138.12093
   PubMed Web of Science ®Google Scholar
• Kneepkens EL, Wei JC, Nurmohamed MT, Yeo KJ, Chen CY, van der Horst-Bruinsma IE, van der Kleij D, Rispens T, Wolbink G, Krieckaert CL. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Ann Rheum Dis 2013; 74:396-401; PMID:24326011; http://dx.doi.org/10.1136/annrheumdis-2013-204185
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665-74; PMID:18486739; http://dx.doi.org/10.1016/S0140-6736(08)60725-4
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675-1684; PMID:18486740; http://dx.doi.org/10.1016/S0140-6736(08)60726-6
   PubMed Web of Science ®Google Scholar
• van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013; 9:164-72; PMID:23399692; http://dx.doi.org/10.1038/nrrheum.2013.4
   PubMed Web of Science ®Google Scholar
• Jung SM, Kim HS, Kim HR, Kim NY, Lee JH, Kim J, Kwok SK, Park KS, Park SH, Kim HY, et al. Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis. Int Immunopharmacol 2014; 21:20-5; PMID:24752013; http://dx.doi.org/10.1016/j.intimp.2014.04.006
   PubMed Web of Science ®Google Scholar
• Roque-Navarro L, Mateo C, Lombardero J, Mustelier G, Fernandez A, Sosa K, Morrison SL, Perez R. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid Hybridomics 2003; 22:245-57; PMID:14511570; http://dx.doi.org/10.1089/153685903322328974
   PubMedGoogle Scholar